SI
SI
discoversearch

Biotech / Medical
Unquoted Biotechs
An SI Board Since July 2001
Posts SubjectMarks Bans
251 25 0
Emcee:  nigel bates Type:  Unmoderated
Place to post interesting stuff for future reference.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
251 CAMBRIDGE, Mass., September 14, 2017 — Moderna Therapeutics, a clinical stage bnigel bates-September 14
250Seems worthy of note, with 5 compounds in PIII, and raising a billion plus... Bnigel bates-August 9
249CAMBRIDGE, Mass., January 13, 2015 — Moderna Therapeutics today announced a licenigel bates-1/13/2015
248(Oxford, UK and Philadelphia, PA, 2 June 2014). Adaptimmune Limited, a leading bnigel bates-6/2/2014
247(Oxford, UK, 8 January 2014) Immunocore Limited, the Oxford-based biotechnology nigel bates-1/8/2014
246(Oxford, UK, 9 July 2013) Immunocore Limited, the Oxford-based biotechnology comnigel bates-7/15/2013
245Sounds too good to be true. Looking forward to the phase-1 trial in a couple of DewDiligence_on_SI16/17/2013
244LONDON, June 17 (Reuters) - British scientists have won early financial backing nigel bates-6/17/2013
243Possibly interesting. They have existing collaborations with Pfizer & Amgen.nigel bates-4/23/2013
242Soon to be quoted... Quintiles. The company gets no cash from this IPO, so it pgo-neil-2/15/2013
241This looks a very interesting project (& they subsequently completed a $38m nigel bates-1/21/2013
240AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreemennigel bates-10/8/2012
239 Interesting analysis of VC returns on the biggest private financings in 2007: lnigel bates-8/30/2012
2384s3 Bioscience, Inc. Secures $20M in Series A Financing Medford, MA, USA, Martnsaf-3/5/2012
237IP Group plc – Portfolio company Oxford Nanopore to commercialise technology in nigel bates-2/1/2012
236Ensemble Therapeutics. Interesting in that its platform involves macrocyclic drtuck-7/21/2011
235Yes. Correct. I've been tongue-in-cheek suggesting, for several years, thascaram(o)uche-6/8/2010
234From the venture cap funding paragraph near the end, I'm guessing Ergonex maIan@SI-5/12/2010
233ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-scaram(o)uche-1/22/2010
232No longer unquoted... <b>Mondobiotech Holding AG goes public on 26th Augughmm-8/27/2009
231>>than Isotechnika...<< Cruel, mentioning them.nigel bates-6/3/2009
230It will be interesting to see if Concert has better success with duterated compotnsaf-6/3/2009
229But too heavy to last, eh?tnsaf-6/3/2009
228Nah. Tritium would be heavy. :)nigel bates16/2/2009
227That's <i>heavy</i>! :-)DewDiligence_on_SI16/2/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.